AZD6482

For research use only.

Catalog No.S1462 Synonyms: KIN-193

22 publications

AZD6482 Chemical Structure

CAS No. 1173900-33-8

AZD6482 (KIN-193) is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.

Selleck's AZD6482 has been cited by 22 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description AZD6482 (KIN-193) is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.
Targets
PI3Kβ [1]
(Cell-free assay)
PI3Kδ [1]
(Cell-free assay)
DNA-PK [1]
(Cell-free assay)
PI3Kα [1]
(Cell-free assay)
10 nM 80 nM 420 nM 870 nM
In vitro

AZD6482 also inhibits PI3Kα, γ, and δ, with IC50 of 80 nM to 1.09 μM, which are significantly lower than its (+)-enantiomer (S-form). AZD6482 is an antiplatelet agent; it blocks platelet activation adhesion/aggregation and promotes platelet disaggregation in assay of washed platelet aggregation (WPA), with an IC50 value of 6 nM. Furthermore, by targeting PI3Kβ, AZD6482 specifically inhibits thrombosis without interfering with normal haemostasis. Therefore, AZD6482 is used as an anti-thrombotic drug for the prophylaxis of thrombotic disorders. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human RXF393 cell Moj5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX;VbFZIUW6qaXLpeIlwdiCxZjDoeY1idiCUWF[zPVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjBzMUW0JO69VQ>? NYXvbI12W0GQR1XS
human SW982 cell NUD6cmhXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlO4TY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFM2QDRizszN MUPTRW5ITVJ?
human MAD-MB-468 cells NHvQc2lHfW6ldHnvckBie3OjeR?= M4fJ[2lvcGmkaYTpc44hd2ZiUFmzT4JmfGFiaX6gbJVu[W5iTVHEMW1DNTR4ODDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFOnckS3N{BCc3RicHjvd5Bpd3K7bHH0bY9vKGK7IHPlcIx2dGG{IIDveIVv[3liYYPzZZktKEmFNUC9NE4xPCEQvF2= MlvkNlQ6QTJ6N{S=
human KURAMOCHI cell MoftS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2POdGlvcGmkaYTpc44hd2ZiaIXtZY4hU1WUQV3PR2hKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMEWxJO69VQ>? NETP[m9USU6JRWK=
human A498 cell NVTvTolLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGE1QThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGxO|k2KM7:TR?= NVfjN5VzW0GQR1XS
human YT cell M2GwR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX\EUI5NUW6qaXLpeIlwdiCxZjDoeY1idiC\VDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVIxPjZizszN MWrTRW5ITVJ?
human VMRC-RCZ cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXXs[WRYUW6qaXLpeIlwdiCxZjDoeY1idiCYTWLDMXJEYiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUS4PVgh|ryP MWHTRW5ITVJ?
human MDA-MB-415 cell NEDFR|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXLJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj20NVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF4N{OyJO69VQ>? MlL1V2FPT0WU
human J82 cell MkLWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYntdXdmUW6qaXLpeIlwdiCxZjDoeY1idiCMOEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4Pzd7IN88US=> NHzQN3lUSU6JRWK=
human SW1710 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGWz[XpKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTJ7MjFOwG0> MkPWV2FPT0WU
human T47D cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF;NfodKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU{OjdizszN NHSyOpJUSU6JRWK=
human SU-DHL-1 cell NWTZbnd1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGroeGFKdmirYnn0bY9vKG:oIHj1cYFvKFOXLVTIUE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC53NkixN{DPxE1? MVXTRW5ITVJ?
human BT-20 cell NWW5ZphsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4DtcWlvcGmkaYTpc44hd2ZiaIXtZY4hSlRvMkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6OjJ{IN88US=> NWjUSXZtW0GQR1XS
human OS-RC-2 cell M4PzbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MojmTY5pcWKrdHnvckBw\iCqdX3hckBQWy2UQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43OjN6ODFOwG0> M2jodXNCVkeHUh?=
human RPMI-6666 cell NYf6b3VrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{i3eWlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST22OlY3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC54NEO3PUDPxE1? NIfDbm5USU6JRWK=
human OVCAR-3 cell NEH5eYNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1i2ZmlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjd7NE[g{txO NETheI1USU6JRWK=
human NALM-6 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEixeGRKdmirYnn0bY9vKG:oIHj1cYFvKE6DTF2tOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzB2NkWg{txO MWHTRW5ITVJ?
human RS4-11 cell Ml\BS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVTTOIhHUW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd|OEC2JO69VQ>? M1riTHNCVkeHUh?=
human SK-MES-1 cell M33jcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVjDOIEyUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSXMuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwN{i5Olch|ryP MV\TRW5ITVJ?
human ES7 cell NESwSYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUfOW|NXUW6qaXLpeIlwdiCxZjDoeY1idiCHU{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlgyOjh4IN88US=> MoXJV2FPT0WU
human NCI-H2342 cell NYnMcXVbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mom4TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzOFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh2Mkm0JO69VQ>? NETFUI5USU6JRWK=
human SCC-9 cell MkfvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKGi3bXHuJHNESy17IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64OVc4KM7:TR?= NV;GVI5JW0GQR1XS
human EW-7 cell NHXjRVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXvyN2JSUW6qaXLpeIlwdiCxZjDoeY1idiCHVz23JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PjN3NjFOwG0> NX;BeWVjW0GQR1XS
human HH cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnjPTY5pcWKrdHnvckBw\iCqdX3hckBJUCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOU[yNlIh|ryP M{mwTnNCVkeHUh?=
human A427 cell M33vPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYDJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm5OVA2KM7:TR?= MnroV2FPT0WU
human Daudi cell MmTSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGRifWSrIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wOlg5QCEQvF2= M1;1cHNCVkeHUh?=
human P30-OHK cell M{KydGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVvaU3dbUW6qaXLpeIlwdiCxZjDoeY1idiCSM{CtU2hMKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5yN{GzPEDPxE1? MnPmV2FPT0WU
human HGC-27 cell MmjNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnW0TY5pcWKrdHnvckBw\iCqdX3hckBJT0NvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4Phfg+9lCCLQ{WwQVEvOThzNjFOwG0> Ml7rV2FPT0WU
human CAMA-1 cell NIfvXo9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWrhbXlPUW6qaXLpeIlwdiCxZjDoeY1idiCFQV3BMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJyMEGg{txO NEOySGRUSU6JRWK=
human SK-OV-3 cell M4LF[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{DEZ2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjB2NESg{txO NH[3TZRUSU6JRWK=
human NCI-H1048 cell NGn5bJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUC0PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjJ3N{mg{txO NV[0RmxjW0GQR1XS
human MEL-HO cell Mlr3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4XheGlvcGmkaYTpc44hd2ZiaIXtZY4hVUWOLVjPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zPDJ|ODFOwG0> M4nMXnNCVkeHUh?=
human NKM-1 cell MmT6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2r2bmlvcGmkaYTpc44hd2ZiaIXtZY4hVkuPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlI5PjN4IN88US=> M1izN3NCVkeHUh?=
human NCI-H650 cel MlPsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M13mdGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjNyMEe2JO69VQ>? M{W5eXNCVkeHUh?=
human HAL-01 cell M4XSN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYLJcohq[mm2aX;uJI9nKGi3bXHuJGhCVC1yMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|AyPzVizszN MmT5V2FPT0WU
human 786-0 cell M1q5Umdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIP4UlVKdmirYnn0bY9vKG:oIHj1cYFvKDd6Nj2wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{OTJ6MzFOwG0> NE\hZ5ZUSU6JRWK=
human GI-1 cell M4[1Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{PmV2lvcGmkaYTpc44hd2ZiaIXtZY4hT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|E5ODhizszN MXzTRW5ITVJ?
human Becker cell M3\wUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV;PUG1yUW6qaXLpeIlwdiCxZjDoeY1idiCEZXPr[ZIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjN4M{G1JO69VQ>? NYPHVXh6W0GQR1XS
human CCF-STTG1 cell NWG2bWZGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlnrTY5pcWKrdHnvckBw\iCqdX3hckBES0ZvU2TUS|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjR{NUK1JO69VQ>? NGHo[JZUSU6JRWK=
human MC116 cell MnWwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn;rTY5pcWKrdHnvckBw\iCqdX3hckBOSzFzNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFYyOjJizszN NHezSHJUSU6JRWK=
human MDA-MB-468 cell NY[2WpMyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX62WmsyUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuPDZ6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT61N|c{PiEQvF2= M1nM[3NCVkeHUh?=
human NB12 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUexZpRGUW6qaXLpeIlwdiCxZjDoeY1idiCQQkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42PDh2MjFOwG0> NEDvVm9USU6JRWK=
human LXF-289 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MULJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU2OTB2IN88US=> NInm[HhUSU6JRWK=
human MFE-296 cell M{f3[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWfJcohq[mm2aX;uJI9nKGi3bXHuJG1HTS1{OU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU3QDN4IN88US=> M2rhR3NCVkeHUh?=
human SNU-423 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{SxdmlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUSyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTdzOUKg{txO M2jpb3NCVkeHUh?=
human NCI-H2291 cell NGjFbXJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX7o[FNxUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIzQTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW3OlEh|ryP MXLTRW5ITVJ?
human OCUB-M cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWfTOHVzUW6qaXLpeIlwdiCxZjDoeY1idiCRQ2XCMW0h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjV6M{G0JO69VQ>? MXLTRW5ITVJ?
human KU812 cell NGPsdIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXXrWXZ{UW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTl4Mkig{txO NGnGdolUSU6JRWK=
human HuO9 cell NI\ZeZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3m5T2lvcGmkaYTpc44hd2ZiaIXtZY4hUHWROTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlEzQCEQvF2= NX7YZXF3W0GQR1XS
human 639-V cell Mn\DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIfmVlRKdmirYnn0bY9vKG:oIHj1cYFvKDZ|OT3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OzF2NDFOwG0> MnjVV2FPT0WU
human HCC70 cell Ml3sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn21TY5pcWKrdHnvckBw\iCqdX3hckBJS0N5MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlYyPDZizszN M4DGWHNCVkeHUh?=
human SNB75 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmjOTY5pcWKrdHnvckBw\iCqdX3hckBUVkJ5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlY2ODhizszN MYjTRW5ITVJ?
human D-336MG cell Mm\IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Moi3TY5pcWKrdHnvckBw\iCqdX3hckBFNTN|Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43Pjh6IN88US=> M2\ndHNCVkeHUh?=
human LoVo cell NXm4bVBJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGxwXm9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkezPFI2KM7:TR?= M3XTeHNCVkeHUh?=
human EB2 cell NVrpPXRpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFTlXW9KdmirYnn0bY9vKG:oIHj1cYFvKEWEMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuO|UxOTlizszN M1;YdHNCVkeHUh?=
human HSC-2 cell MoLCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWnJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT63OVczPyEQvF2= NFe5dnVUSU6JRWK=
human D-542MG cell M{ixZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnXVTY5pcWKrdHnvckBw\iCqdX3hckBFNTV2Ml3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45PTB5NzFOwG0> NFLBTG5USU6JRWK=
human COLO-684 cell MkLlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWjSSXlPUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMkCwN|Ih|ryP MUHTRW5ITVJ?
human GDM-1 cell Mlq4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGdFVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yOFIxPiEQvF2= NYrSS25wW0GQR1XS
human SW1088 cell MnzUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVLJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOFgyPDNizszN MnrVV2FPT0WU
human SF295 cell NFjjN3lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1TtNGlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z{OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlc3QTV3IN88US=> M4\uRXNCVkeHUh?=
human NCI-H2030 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3xZ5pVUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxOzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmwNlg5KM7:TR?= Mo\uV2FPT0WU
human NCI-H1755 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnG5TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3OVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ5ME[zJO69VQ>? NHfpOGJUSU6JRWK=
human MDA-MB-361 cell NGj3O2FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUHmU3NvUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz61NlcxQSEQvF2= M{fNeHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:[1]
- Collapse

Assay of PI3K enzyme inhibition:

The inhibition of PI3Kβ, PI3Kα, PI3Kγ, and PI3Kδ is evaluated in an AlphaScreen based enzyme activity assay using human recombinant enzymes. The assay measures PI3K-mediated conversion of PIP2 to PIP3. Biotinylated PIP3, a GST-tagged pleckstrin homology (PH) domain and the two AlphaScreen beads form a complex that elicits a signal upon laser excitation at 680 nm. The PIP3 formed in the enzyme reaction competes with the biotinylated PIP3 for binding to the PH domain thus reducing the signal with increasing enzyme product. The AZD6482 is dissolved in DMSO and added to 384 well plates. PBKβ, PBKα, PBKγ, or PBKδ is added in a Tris buffer (50 mM Tris pH 7.6, 0.05% CHAPS, 5 mM DTT, and 24 mM MgCl2) and allowed to preincubate with AZD6482 for 20 minutes prior to the addition of substrate solution containing PIP2 and ATP. The enzyme reaction is stopped after 20 minutes by addition of stop solution containing EDTA and biotin-PIP3, followed by addition of detection solution containing GST-grpl PH and AlphaScreen beads. Plates are left for a minimum of 5 hours in the dark prior to analysis. The final concentration of DMSO, ATP and PIP2 in the assay are, 0.8%, 4 μM, and 40 μM, respectively. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
Cell Research:[1]
- Collapse
  • Cell lines: Human platelet pellet
  • Concentrations: 0–60 nM, dissolved in DMSO
  • Incubation Time: 5 min
  • Method: For assay of washed platelet aggregation (WPA), the platelet pellets are isolated from human blood and re-suspended to 2 × 1015/L in Tyrodes buffer (TB) containing 1 μM hirudin and 0.02 U/mL apyrase. Then, the platelet suspension is left to rest at room temperature for 30 min. Just prior to time for assay, CaCl2 is added to a final concentration of 2 mM. AZD6482, dissolved in DMSO, is added to a 96-well plate prior to the addition of the washed platelet suspension. The platelet suspension is preincubated with AZD6482 for 5 min. Light absorption at 650 nm is recorded before and after a 5 min plate shake and referred to as recording 0 (R0) and Rl. A mouse anti-human CD9 antibody is added (at a donor specific concentration) to each well prior to next 10 min plate shake and light absorption recording; R2. For data analysis, light absorbance in wells with TB are subtracted from all readings before percent aggregation is calculated according the formula: [(R1-R2)/R1] × 100 = % aggregation. Spontaneous aggregation or pro-aggregatory effect of the inhibitor is evaluated by the same formula, [(R0-Rl)/R0] × 100 = % aggregation. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (200.75 mM)
Ethanol 10 mg/mL (24.48 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 408.45
Formula

C22H24N4O4

CAS No. 1173900-33-8
Storage powder
in solvent
Synonyms KIN-193
Smiles CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3C(=O)O)N4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy AZD6482 | AZD6482 supplier | purchase AZD6482 | AZD6482 cost | AZD6482 manufacturer | order AZD6482 | AZD6482 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID